Pyoderma gangrenosum
Le Pyoderma gangrenosum est une maladie cutanée inflammatoire rare dans laquelle des pustules ou nodules douloureux se transforment en ulcères qui se développent progressivement. Pyoderma gangrenosum n’est pas infectieux. Les traitements peuvent inclure des corticostéroïdes, de la ciclosporine ou divers anticorps monoclonaux. Bien qu’elle puisse toucher des personnes de tout âge, elle touche principalement les personnes entre 40 et 50 ans.
☆ Dans les résultats du Stiftung Warentest 2022 en Allemagne, la satisfaction des consommateurs avec ModelDerm n'était que légèrement inférieure à celle des consultations de télémédecine payantes.
Sur la jambe d'une personne atteinte de colite ulcéreuse.
References
Pyoderma gangrenosum est une affection cutanée rare qui provoque des ulcères douloureux aux bords rouges ou violacés. Elle est classée comme maladie inflammatoire et fait partie d’un groupe appelé dermatoses neutrophiles. La cause de pyoderma gangrenosum est complexe et implique des problèmes d’immunité à la fois innée et adaptative chez les personnes génétiquement prédisposées. Récemment, les chercheurs se sont concentrés sur le follicule pileux comme point de départ potentiel de la maladie.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum est une affection cutanée rare provoquant des ulcères extrêmement douloureux. Même si nous n’en comprenons pas entièrement la cause, nous savons qu’elle implique une activité accrue de certaines cellules immunitaires. Traiter la maladie n’est toujours pas facile. Nous disposons de divers médicaments qui suppriment le système immunitaire ou modifient son activité. Parallèlement, nous nous concentrons également sur le traitement des plaies et la gestion de la douleur. Les corticostéroïdes et la cyclosporine sont souvent le premier choix de traitement, mais dernièrement, de plus en plus de recherches ont été menées sur l'utilisation de thérapies biologiques comme les inhibiteurs du TNF-α. Ces produits biologiques sont de plus en plus préférés, en particulier chez les patients souffrant d'autres affections inflammatoires, et ils sont utilisés plus tôt dans le processus pathologique.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
